Bruker Announces $500 Million Private Placement of Senior Notes to Support Strategic Growth Objectives
December 08 2021 - 7:00AM
Business Wire
Bruker Corporation (Nasdaq: BRKR) announced today that it has
completed a new private placement of 10-year senior notes in the
aggregate principal amount of $500 million to enhance its financial
flexibility and fund strategic growth objectives.
Gerald Herman, Bruker’s Executive Vice President & Chief
Financial Officer, commented “This new debt financing capitalizes
on the low interest rate environment in European capital markets,
locks in attractive fixed rates for the next decade, and provides
Bruker with significantly expanded capacity to continue investment
in our Project Accelerate 2.0 initiatives and future strategic
opportunities.”
Under private placement note terms, 300 million Swiss Franc
0.88% Series A senior notes and 150 million Euro 1.03% Series B
senior notes due December 8, 2031, were issued and sold to a
limited number of accredited institutional investors in an offering
exempt from the registration requirements of the Securities Act of
1933, as amended.
Bruker intends to use proceeds from this financing for general
corporate purposes, including the repayment of maturing debt
obligations and to support strategic growth objectives.
The new financing arrangements are subject to customary
affirmative and negative covenants and other terms as detailed in a
filing with the Securities and Exchange Commission on Form 8-K,
dated December 8, 2021.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
Forward Looking Statements
Any statements contained in this press release which do not
describe historical facts may constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements regarding the expected interest cost
reduction associated with the financing arrangements. Any
forward-looking statements contained herein are based on current
expectations, but are subject to risks and uncertainties that could
cause actual results to differ materially from those indicated,
including, but not limited to, risks and uncertainties relating to
adverse changes in conditions in the global economy and volatility
in the capital markets, fluctuations in foreign currency exchange
rates, our ability to successfully implement and execute on our
capital management initiatives, our ability to maintain our
leverage and interest coverage ratios required by the financing
arrangements, our ability to make payments on our financial
obligations when they become due, and other risk factors discussed
from time to time in our filings with the Securities and Exchange
Commission, or SEC. These and other factors are identified and
described in more detail in our filings with the SEC, including,
without limitation, our annual report on Form 10-K for the year
ended December 31, 2020. We expressly disclaim any intent or
obligation to update these forward-looking statements other than as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211208005547/en/
Investor Relations Bruker Corporation T: +1 (978) 663 – 3660,
ext. 1479 E: Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024